Patrick Marcellin
YOU?
Author Swipe
View article: Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation
Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation Open
View article: Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety Open
INTRODUCTION: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior renal and bone safety. We repo…
View article: Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells Open
View article: Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D <scp>HBeAg</scp>‐positive chronic hepatitis B
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D <span>HBeAg</span>‐positive chronic hepatitis B Open
Summary Backgrounds and Aims We investigated associations between hepatitis B virus (HBV) genome‐length haplotype number (HN) at baseline in subjects with HBeAg‐positive chronic hepatitis B (CHB), and the likelihood of achieving functional…
View article: Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients
Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients Open
Background The SAF score (steatosis, activity, and fibrosis) has been developed for the assessment of the histological severity of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The aim of this study was …
View article: Staging Fibrosis in Chronic Viral Hepatitis
Staging Fibrosis in Chronic Viral Hepatitis Open
Staging fibrosis accurately has always been a challenge in viral hepatitis and other liver diseases. Liver biopsy is an imperfect gold standard due to its intra and interobserver agreement limitations and additional characteristics such as…
View article: Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B Open
View article: Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection
Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection Open
Liver biopsies from patients with chronic hepatitis B were submitted to RNA-Seq and multiplex immunofluorescence and identified two different liver immune microenvironments: immune high and immune low. Immune high patients showed elevated …
View article: Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B Open
BACKGROUND Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety ofpegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and …
View article: New therapies for hepatitis delta virus infection
New therapies for hepatitis delta virus infection Open
Hepatitis delta virus (HDV) infection is a defective virus requiring hepatitis B virus (HBV) for its complete replication cycle. HDV is a small hepatotropic RNA virus and around 15 to 25 million people worldwide are living with chronic hep…
View article: Genome-to-genome analysis identifies an Asian-specific variant in the gene encoding NTCP that leads to specific HBV escape mutations during chronic infection
Genome-to-genome analysis identifies an Asian-specific variant in the gene encoding NTCP that leads to specific HBV escape mutations during chronic infection Open
GR-FE
View article: Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study Open
The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a and ribavirin (RBV) in treatmen…
View article: A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care Open
Chronic infection with the hepatitis C virus (HCV) is a leading cause of global morbidity and mortality. While recent advances in antiviral therapy have led to significant improvements in treatment response rates, only a minority of infect…
View article: IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)
IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) Open
Background Potent antivirals can reduce HCC incidence in CHB. TDF and TAF are first-line treatments, and in Phase 3 studies through 3 years, TAF has shown antiviral efficacy similar to TDF, higher rates of ALT normalization, and no resista…
View article: Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials
Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials Open
View article: Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease
Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease Open
View article: Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B
Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B Open
View article: Targeted long read sequencing reveals the comprehensive architecture and expression patterns of integrated HBV DNA in CHB liver biopsies
Targeted long read sequencing reveals the comprehensive architecture and expression patterns of integrated HBV DNA in CHB liver biopsies Open
View article: Characterization of serologic responses following ALT flares in >3000 CHB patients pooled from 5 clinical trials
Characterization of serologic responses following ALT flares in >3000 CHB patients pooled from 5 clinical trials Open
View article: Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment Open
View article: Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort
Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort Open
Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real‐wo…
View article: Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B Open
Sustained off-treatment immune control is achieved with peginterferon alfa-2a in a real-world setting. HBsAg clearance 3 years after completion of peginterferon alfa-2a can be predicted on the basis of on-treatment HBsAg kinetics.
View article: Future treatments for hepatitis delta virus infection
Future treatments for hepatitis delta virus infection Open
Around 15‐20 million people develop chronic hepatitis delta virus worldwide. Hepatitis delta virus (HDV) is a defective RNA virus requiring the presence of the hepatitis B virus surface antigen (HBsAg) to complete its life cycle. HDV infec…
View article: Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B Open
In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion ar…
View article: Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients Open
Despite the high global prevalence of chronic hepatitis B (CHB) infection, datasets covering the whole hepatitis B viral genome from large patient cohorts are lacking, greatly limiting our understanding of the viral genetic factors involve…
View article: Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection Open
Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF treatment for up to 10 years in a well‐described cohort of CHB pati…
View article: Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort Open
View article: Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy Open
View article: Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study Open
View article: Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study
Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study Open
Treatment options for Hepatitis C infection have greatly improved with direct-acting antiviral (DAA) combinations achieving high cure rates. Nevertheless, the cost of this treatment is still high and access to treatment in many countries h…